CVKD vs. MGNX, PLRX, IFRX, SAVA, HLVX, ATOS, COYA, TCRX, ANRO, and SRZN
Should you be buying Cadrenal Therapeutics stock or one of its competitors? The main competitors of Cadrenal Therapeutics include MacroGenics (MGNX), Pliant Therapeutics (PLRX), InflaRx (IFRX), Cassava Sciences (SAVA), HilleVax (HLVX), Atossa Genetics (ATOS), Coya Therapeutics (COYA), TScan Therapeutics (TCRX), Alto Neuroscience (ANRO), and Surrozen (SRZN). These companies are all part of the "pharmaceutical products" industry.
Cadrenal Therapeutics vs. Its Competitors
Cadrenal Therapeutics (NASDAQ:CVKD) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.
7.9% of Cadrenal Therapeutics shares are held by institutional investors. Comparatively, 96.9% of MacroGenics shares are held by institutional investors. 26.1% of Cadrenal Therapeutics shares are held by insiders. Comparatively, 13.0% of MacroGenics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Cadrenal Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, MacroGenics has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500.
Cadrenal Therapeutics presently has a consensus price target of $32.00, suggesting a potential upside of 143.35%. MacroGenics has a consensus price target of $3.60, suggesting a potential upside of 126.42%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Cadrenal Therapeutics is more favorable than MacroGenics.
In the previous week, Cadrenal Therapeutics had 1 more articles in the media than MacroGenics. MarketBeat recorded 3 mentions for Cadrenal Therapeutics and 2 mentions for MacroGenics. MacroGenics' average media sentiment score of 1.53 beat Cadrenal Therapeutics' score of 0.96 indicating that MacroGenics is being referred to more favorably in the news media.
Cadrenal Therapeutics has higher earnings, but lower revenue than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.
Cadrenal Therapeutics has a net margin of 0.00% compared to MacroGenics' net margin of -21.99%. MacroGenics' return on equity of -40.24% beat Cadrenal Therapeutics' return on equity.
Summary
MacroGenics beats Cadrenal Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Cadrenal Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CVKD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CVKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cadrenal Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CVKD) was last updated on 9/13/2025 by MarketBeat.com Staff
Free CVKD Stock Alerts